Pathogenesis of anaemia in the critically ill patient

References

• Jelkmann W. Erythropoietin: Structure, control of production, and function. Physiol Rev 1992; 72: 449–89.
   PubMed Web of Science ®Google Scholar
• Annable L, Cotes PM, Mussett MV. The second international reference preparation of erythropoietin, human, urinary, for bioassay. Bull Organ Mond Santé 1972; 47: 99–112.
   PubMed Web of Science ®Google Scholar
• Koury ST, Bondurant MC, Koury MJ. Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridization. Blood 1988; 71: 524–7.
   Google Scholar
• Lacombe C, Da Silva J-L, Bruneval P et al. Peritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidney. J Clin Invest 1988; 81: 620–3.
   PubMed Web of Science ®Google Scholar
• Bachmann S, Le Hir M, Eckardt K-U. Co-localization of erythropoietin mRNA and ecto-5'-nucleotidase immuno-reactivity in peritubular cells of rat renal cortex indicates that fibroblasts produce erythropoietin. J Histochem Cytochem 1993; 41: 335–41.
   Google Scholar
• Koury ST, Bondurant MC, Koury MJ, Semenza GL. Localization of cells producing erythropoietin in murine liver by in situ hybridization. Blood 1991; 77: 2497–503.
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Koury ST, Bohrer M, Salceda S, Caro J. Cellular sites of extrarenal and renal erythropoietin production in anaemic rats. Br J Haematol 1992; 81: 153–9.
   Google Scholar
• Bondurant MC, Koury MJ. Anemia induces accumulation of erythropoietin mRNA in the kidney and liver. Mol Cell Biol 1986; 6: 2731–3.
   PubMed Web of Science ®Google Scholar
• Pagel H, Jelkmann W, Weiss C. A comparison of the effects of renal artery constriction and anemia on the production of erythropoietin. Pflugers Arch 1988; 413: 62–6.
   Google Scholar
• Pagel H, Jelkmann W, Weiss C. 02-supply to the kidneys and the production of erythropoietin. Respir Physiol 1989; 77: 111–18.
   Google Scholar
• Goldberg MA, Glass GA, Cunningham JM, Bunn HF. The regulated expression of erythropoietin by two human hepatoma cell lines. Proc Natl Acad Sci USA 1987; 84: 7972–6.
   PubMed Web of Science ®Google Scholar
• Goldberg MA, Dunning SP, Bunn HF. Regulation of the erythropoietin gene: evidence that the oxygen sensor is a heme protein. Science 1988; 242: 1412–15.
   Google Scholar
• Fandrey J, Seydel FP, Siegers C-P, Jelkmann W. Role of cytochrome P450 in the control of the production of erythropoietin. Life Sci 1990; 47: 127–34.
   Google Scholar
• Fandrey J, Frede S, Jelkmann W. Role of hydrogen peroxide in hypoxia-induced erythropoietin production. Biochem. J. 1994; 303: 507–10.
   Google Scholar
• Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995; 270: 1230–7.
   PubMed Web of Science ®Google Scholar
• Watowich SS, Yoshimura A, Longmore GD, Hilton DG, Yoshimura Y, Lodish HF. Homodimerization and constitutive activation of the erythropoietin receptor. Proc Natl Acad Sci USA 1992; 89: 2140–4.
   PubMed Web of Science ®Google Scholar
• Miura O, Ihle JN. Dimer- and oligomerization of the erythropoietin receptor by disulfide bond formation and significance of the region near the WSXVVS motif in intracellular transport. Arch Biochem Biophys 1993; 306: 200–8.
   PubMed Web of Science ®Google Scholar
• Tanner JVV, Chen W, Young RL, Longmore GD, Shaw AS. The conserved Box 1 motif of cytokine receptors is required for association with JAK kinases. J Biol Chem 1995; 270: 6523–30.
   Google Scholar
• Koury MJ, Bondurant MC. The molecular mechanism of erythropoietin action. Eur J Biochem 1992; 210: 649–63.
   PubMedGoogle Scholar
• Scott T, Eagleson M (Eds). Concise Encyclopedia: Biochemistry, 2nd ed. Berlin, deGruyter & Co, 1988, 255 ff.
   Google Scholar
• Chernow B, Salem M, Stacey JA. Blood conservation - a critical care imperative. Grit Care Med 1991; 19: 313–14.
   Google Scholar
• Lee GR. The anemia of chronic disease. Semin Hematol 1983; 20: 61–6.
   PubMed Web of Science ®Google Scholar
• Broxmeyer HE, Lu L, Platzer E, Feit C, Juliano L, Rubin BY. Comparative analysis of the influences of human gamma, alpha and beta interferons on human multipotential (CFU-GEMM), erythroid (BFU-E) and granulocyte-macrophage (CFU-GM) progenitor cells. J Immunol 1983; 131: 1300–5.
   PubMed Web of Science ®Google Scholar
• Zoumbos NC, Djeu JY, Young NS. Interferon is the suppressor of hematopoiesis generated by stimulated lymphocytes in vitro. J Immunol 1984; 133: 769–74.
   Google Scholar
• Mamus SW, Beck-Schroeder S, Zanjani ED. Suppression of normal human erythropoiesis by gamma interferon in vitro. J Clin Invest 1985; 75: 1496–503.
   PubMed Web of Science ®Google Scholar
• Murphy M, Perussia B, Trinchieri G. Effects of recombinant tumor necrosis factor, lymphotoxin, and immune interferon on proliferation and differentiation of enriched hematopoietic precursor cells. Exp Hematol 1988; 16: 131–8.
   Google Scholar
• Means RT, Krantz SB. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 1992; 80: 1639–47.
   PubMed Web of Science ®Google Scholar
• Means RT, Krantz SB. Inhibition of human erythroid colony-forming units by y interferon can be corrected by recombinant human erythropoietin. Blood 1991; 78: 2564–7.
   PubMed Web of Science ®Google Scholar
• Akahane K, Hosoi T, Urabe A, Kawakami M, Takaku F. Effects of recombinant human tumor necrosis factor (rhTNF) on normal human and mouse hemopoietic progenitor cells. Int J Cell Cloning 1987; 5: 16–26.
   Google Scholar
• Roodman GD, Bird A, Hutzler D, Montgomery W. Tumor necrosis factor-alpha and hematopoietic progenitors: effects of tumor necrosis factor on the growth of erythroid progenitors CFU-E and BFU-E and the hematopoietic cell lines K562, HL60, and HEL cells. Exp Hematol 1987; 15: 928–35.
   PubMed Web of Science ®Google Scholar
• Means RT, Des sypris EN, Krantz SB. Inhibition of human erythroid colony-forming units by tumor necrosis factor requires accessory cells. J Clin Invest 1990; 86: 538–41.
   PubMed Web of Science ®Google Scholar
• Blick M, Sherwin SA, Rosenblum M, Guttermann J. Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res 1987; 47: 2986–9.
   PubMed Web of Science ®Google Scholar
• Tracey KJ, Wei H, Manogue KR et al. Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. J Exp Med 1988; 167: 1211–27.
   PubMed Web of Science ®Google Scholar
• Johnson CS, Cook CA, Furmanski P. In vivo suppression of erythropoiesis by tumor necrosis factor-a (TNF-a): Reversal with exogenous erythropoietin (EPO). Exp Hematol 1990; 18: 109–13.
   Google Scholar
• Dybedal I, Jacobsen SEW. Transforming growth factor f3 (TGF-13), a potent inhibitor of erythropoiesis: Neutralizing TGF-13 antibodies show erythropoietin as a potent stimulator of murine burst-forming unit erythroid colony formation in the absence of a burst-promoting activity. Blood 1995; 86: 949–57.
   PubMed Web of Science ®Google Scholar
• Miller KL, Carlino JA, Ogawa Y, Avis PD, Carrol KG. Alterations in erythropoiesis in TGF-131-treated mice. Exp Hematol 1992; 20: 951–6.
   Google Scholar
• Chuncharunee S, Carter CD, Studtmann KE, Caro J, Coffey RJ, Dessypris EN. Chronic administration of transforming growth factor-beta suppresses erythropoietin-dependent erythropoiesis and induces tumour necorsis factor in vivo. Br J Haematol 1993; 84: 374–80.
   PubMed Web of Science ®Google Scholar
• Maury CPJ, Andersson LC, Teppo A-M, Partanen S, Juvonen E. Mechanism of the anaemia in rheumatoid arthritis: Demonstration of raised interleukin 113 concentrations in anaemic patients and of interleukin 1 mediated suppression of normal erythropoiesis and proliferation of human erythroleukemia (HEL) cells in vivo. Ann Rheum Dis 1988; 47: 972–8.
   Google Scholar
• Schooley JC, Kullgren B, Allison AC. Inhibition by interleukin-1 of the action of erythropoietin on erythroid precursors and its possible role in the pathogenesis of hypoplastic anaemias. Br J Haematol 1987; 67: 11–17.
   Google Scholar
• Johnson CS, Keckler DJ, Topper MI, Braunschweiger G, Furmanski P. In vivo hematopoietic effects of recombinant interleukin-1 in mice: stimulation of granulocytic, monocytic, magakaryocytic, and early erythroid progenitors, suppression of late-stage erythropoiesis, and reversal of erythroid suppression with erythropoietin. Blood 1989; 73: 678–83.
   Google Scholar
• Johnson CS, Pourbohloul SC, Furmanski P. Negative regulators of in vivo erythropoiesis: Interaction of IL-113 and TNF-a and the lack of a strict requirement for T or NK cells for their activity. Exp Hematol 1991; 19: 101–5.
   Google Scholar
• Means RT, Dessypris EN, Krantz SB. Inhibition of human erythroid colony-forming units by interleukin-1 is mediated by gamma interferon. J Cell Physiol 1992; 150: 59–66.
   Google Scholar
• Schwartz GN, Neta R. Vigneulle RM, Patchen ML, Mac VittieTJ. Recovery of hematopoietic colony-forming cells in irradiated mice pretreated with interleukin 1 (IL-1). Exp Hematol 1988; 16: 752–7.
   Google Scholar
• Zucali JR, Moreb J, Gibbons W et al. Radioprotection of hematopoietic stem cells by interleukin-1. Exp Hematol 1994; 22: 130–5.
   PubMed Web of Science ®Google Scholar
• Neta R, Oppenheim JJ, Wang JM, Snapper CM, Moorman MA, Dubois CM. Synergy of IL-1 and stem cell factor in radioprotection of mice is associated with IL-1 up-regulation of mRNA and protein expression for c-kit on bone marrow cells. J Immunol 1994; 153: 1536–43.
   PubMed Web of Science ®Google Scholar
• Knowles RG, Moncada S. Nitric oxide synthases in mammals. Biochem J 1994; 298: 249–58.
   PubMed Web of Science ®Google Scholar
• Maciejewski JP, Selleri C, Sato T et al. Nitric oxide suppression of human hematopoiesis in vitro. J Clin Invest 1995; 96: 1085–92.
   PubMed Web of Science ®Google Scholar
• Fuchs D, Hausen A, Reibnegger G et al. Immune activation and the anaemia associated with chronic inflammatory disorders. Eur J Haematol 1991; 46: 65–70.
   PubMed Web of Science ®Google Scholar
• Camacho J, Arnalich F, Zamorano AF, Velazquez JJ. Serum erythropoietin levels in the anaemia of chronic disorders. J Intern Med 1991; 229: 49–54.
   PubMed Web of Science ®Google Scholar
• Ebrahim O, Folb PI, Robson SC, Jacobs P. Blunted erythropoietin response to anaemia in tuberculosis. Eur J Haematol 1995; 55: 251–4.
   PubMed Web of Science ®Google Scholar
• Baer AN, Dessypris EN, Goldwasser E, Krantz SB. Blunted erythropoietin response to anaemia in rheumatoid arthritis. Br J Haematol 1987; 66: 559–64.
   PubMed Web of Science ®Google Scholar
• Hochberg MC, Arnold CM, Hogans BB, Spivak JL. Serum immunoreactive erythropoietin in rheumatoid arthritis: impaired response to anemia. Arthritis Rheum 1988; 31: 1318–21.
   PubMed Web of Science ®Google Scholar
• Vreugdenhil G, Swaak AJG. The role of erythropoietin in the anaemia of chronic disease in rheumatoid arthritis. Clin Rheumatol 1990; 9: 22–7.
   PubMed Web of Science ®Google Scholar
• Gasché C, Reinisch W, Lochs H et al. Anemia in Crohn's disease. Dig Dis Sci 1994; 39: 1930–4.
   PubMed Web of Science ®Google Scholar
• HorinaJH, Petritsch W, Schmid CR et al. Treatment of anemia in inflammatory bowel disease with recombinant human erythropoietin: Results in three patients. Gastroenterology 1993; 104: 1828–31.
   PubMed Web of Science ®Google Scholar
• Miller CB, Jones RJ, Piantadosi S, Abeloff MD, Spivak JL. Decreased erythropoietin response in patients with the anemia of cancer. New Engl J Med 1990; 322: 1689–92.
   Google Scholar
• Rogiers P, Zhang H, Leeman M, Neels H, Melot C, Vincent JL. Erythropoietin response is blunted in critically ill patients. Intensive Care Med 1997; 23: 159–62.
   PubMed Web of Science ®Google Scholar
• Hobisch-Hagen P. Mayr A, Herold M et al. Ann Hematol 1997; 74: A174.
   Google Scholar
• Jelkmann W, Wolff M, Fandrey J. Modulation of the production of erythropoietin by cytokines: In vitro studies and their clinical implications. Contrib Nephrol 1990; 87: 68–77.
   Google Scholar
• Jelkmann W, Pagel H, Wolff M, Fandrey J. Monokines inhibiting erythropoietin production in human hepatoma cultures and isolated perfused rat kidneys. Life Sci 1992; 50: 301–8.
   PubMed Web of Science ®Google Scholar
• Faquin WC, Schneider TJ, Goldberg MA. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 1992; 79: 1987–94.
   Google Scholar
• Fandrey J, Huwiler A, Frede S, Pfeilschifter J, Jelkmann W. Distinct signaling pathways mediate phorbolester-induced and cytokine-induced inhibition of erythropoietin gene expression. Eur Biochem 1994; 226: 335–40.
   Google Scholar
• Leng HMJ, Kidson SH, Keraan MM, Randall GW, Folb PI. Cytokine-mediated inhibition of erythropoietin synthesis by dexamethasone. J Pharm Pharmacol 1996; 48: 971–4.
   Google Scholar
• Jelkmann W, Wolff M, Fandrey J. Inhibition of erythropoietin production by cytokines and chemotherapy may contribute to the anemia in malignant diseases. In: Vaupel P, Zander R, Bruley DF (Eds). Oxygen Transport to Tissue XV. New York, Plenum Press, 1994, 525–30.
   Google Scholar
• Jelkmann W, Fandrey J, Frede S, Pagel H. Inhibition of erythropoietin production by cytokines. Ann NY Acad Sci 1994, 718: 300–11.
   PubMed Web of Science ®Google Scholar
• Bigdeli N, Marshall RC, Grabow L, Loh WH. TGF-beta inhibits proliferation of the HepG2 cell line in vitro with concomittant decreases in erythropoietin and a-fetoprotein production. Proc Am Assoc Cancer Res 1992; 33: 436 (Abstr).
   Google Scholar
• Frede S, Fandrey J, Pagel H, Hellwig T, Jelkmann W. Erythropoietin gene expression is suppressed after lipopoly-saccharide or interleukin-1 13 injections in rats. Am J Physiol 1997; 273: R1067–71.
   Google Scholar
• Udupa KB, Lipschitz DA. Endotoxin-induced suppression of erythropoiesis: The role of erythropoietin and a heme synthesis stimulating factor. Blood 1982; 59: 1267–71.
   PubMed Web of Science ®Google Scholar
• Huie ML, Gordon AS, Mirand EA, Leong S, Preti RA, Naughton BA. The effects of interferon on murine erythropoiesis. Life Sci 1985; 36: 2459–62.
   PubMed Web of Science ®Google Scholar
• Johnson RA, Waddelow TA, Caro J, Oliff A, Roodman GD. Chronic exposure to tumor necrosis factor in vivo preferentially inhibits erythropoiesis in nude mice. Blood 1989; 74: 130–8.
   Google Scholar
• Abel J, Spannbrucker N, Fandrey J, Jelkmann W. Serum erythropoietin levels in patients with sepsis and septic shock. Eur J Haematol 1996; 57: 359–63.
   PubMed Web of Science ®Google Scholar
• Schobersberger W, Hoffmann G, Fandrey J. Nitric oxide donors suppress erythropoietin production in vitro. Pflugers Arch 1996; 432: 98085.
   Google Scholar
• Weiss G, Wachter H, Fuchs D. Linkage of cell-mediated immunity to iron metabolism. Immunol Today 1995; 16: 495–500.
   Google Scholar
• Kolb H, Kolb-Bachofen V. Nitric oxide: a pathogenetic factor in autoimmunity. Immunol Today 1992; 13: 157–160.
   PubMedGoogle Scholar
• Weiss G, Goossen B, Doppler W. Translational regulation via iron responsive elements by nitric oxide/NO- synthase pathway. EMBO J 1993; 12: 3651–7.
   Google Scholar
• Klebanoff SJ. Phagocytic cells: Products of oxygen metabolism. In: Gallin JI, Goldstein IM, SnydermanR (Eds). Inflammation: Basic Principles and Clinical Correlates. New York, Raven Press Ltd, 1992, 391–444.
   Google Scholar
• Weiss G, Fuchs D, Hausen A et al. Iron modulates interferon-gamma effects in the human myelomonocytic cells line THP-1. Exp Hematol 1992; 20: 605–10.
   PubMed Web of Science ®Google Scholar
• Fuchs D, Hausen A, Reibnegger G, Werner ER, Dierich MP, Wachter H: Neopterin as a marker for activated cell-mediated immunity: Application in HIV infection. Immunol Today 1988; 9: 150–5.
   PubMedGoogle Scholar
• Fuchs D, Weiss G, Reibnegger G, Wachter H. The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious and malignant diseases. Crit Rev Clin Lab Sci 1992; 29: 307–41.
   PubMed Web of Science ®Google Scholar
• Fuchs D, Weiss G, Wachter H. Neopterin, biochemistry and clinical use as a marker for cellular immune reactions. Int Arch Allergy Immunol 1993; 101: 1–6.
   PubMed Web of Science ®Google Scholar
• Fuchs D, Spira TJ, Hausen A et al. Neopterin as a predictive marker for disease progression in human immunodeficiency virus type 1 infection. Clin Chem 1989; 35: 1746–9.
   PubMed Web of Science ®Google Scholar
• Fahey JL, Taylor JM, Detels R et al. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type-1. New Engl J Med 1990; 322: 166–72.
   PubMed Web of Science ®Google Scholar
• Reibnegger G, Fuchs D, Fuith LC, Hausen A, Werner-Felmayer G, Wachter H. Neopterin as a marker for activated cell-mediated immunity: Application in malignant disease. Cancer Detect Prevent 1991; 15: 483–90.
   Google Scholar
• Strohmaier W, Redl H, Schlag G, Inthorn D. D-erythro-neopterin plasma levels in intensive care patients with and without septic complications. Crit Care Med 1987; 15: 757–62.
   PubMed Web of Science ®Google Scholar
• Denz H, Huber P, Landmann R, Orth B, Wachter H, Fuchs D. Association between the activation of macrophages, changes of iron metabolism and the degree of anaemia in patients with malignant disorders. Eur J Haematol 1992; 48: 244–8.
   PubMed Web of Science ®Google Scholar
• Wachter H, Artner-Dworzak E, Fuchs D et al. Association between neopterin and iron metabolism in cancer patients.Tumor Diagnostik & Therapie 1991; 11: 229–32.
   Google Scholar
• Fuith LC, Fuchs D, Hausen A et al. Decreased haemoglobulin and chronic immune activation in patients with gynaecological malignancies. Eur J Haematol 1990; 45: 280–2.
   PubMed Web of Science ®Google Scholar
• Fuchs D, Zangerle R, Artner-Dworzak E et al. Association between immune activation, changes of iron metabolism and anaemia in patients with HP/-infection. Eur J Haematol 1993; 50: 90–4.
   PubMed Web of Science ®Google Scholar
• Weiss G, Fuchs D, Hausen A et al. Neopterin modulates toxicity mediated by reactive oxygen and chloride species. FEBS Lett 1993; 321: 89–92.
   PubMed Web of Science ®Google Scholar
• Hoffmann G, Schobersberger W, Frede S et al. Neopterin activates transcription factor nuclear factor-kB in vascular smooth muscle cells. FEBS Lett 1996; 391: 181–4.
   PubMed Web of Science ®Google Scholar
• Schobersberger W, Hoffmann G, Grote J. Wachter H, Fuchs D. Induction of inducible nitric oxide synthase expression by neopterin in vascular smooth muscle cells. FEBS Lett 1995; 377: 461–4.
   Google Scholar
• Hoffmann G, Frede S, Kenn S et al. Neopterin-induced TNF-a synthesis in vascular smooth muscle cells. Int Arch Allergy Immunol 1998. (In press.)
   Google Scholar
• Schobersberger W, Jelkmann W, Fandrey J, Frede S, Wachter H, Fuchs D. Neopterin-induced suppression of erythropoietin production in vitro. Pteridines 1995; 6: 12–16.
   Web of Science ®Google Scholar
• Pagel H, Schobersberger W, Fuchs D, Jelkmann W. Pflugers Arch 1998; 435(Suppl): R214.
   Google Scholar